Project Launch: Innovative Plasma Technology for the Gentle Treatment of Precancerous Cervical Lesions
How can precancerous cervical lesions be treated effectively while preserving tissue? This is the question addressed by LtAPD-AI, a new research project by Erbe Elektromedizin GmbH and Tübingen University Women’s Hospital.
The project focuses on further developing an innovative treatment technology based on low-thermal argon plasma (LtAPD). The aim is to create an effective alternative to existing surgical procedures for HPV-related cervical tissue changes, with as few side effects as possible.
A key area of innovation is the combination of plasma technology with additional AI-powered technologies. These are intended to enable precise dosing, thereby improving treatment quality and usability.
The project partners are also exploring further medical applications, particularly in minimally invasive procedures, as well as integration into digital documentation systems.
The LtAPD-AI pilot project also provides an opportunity to test services offered by the industry-in-clinic platform being established jointly by BioRegio STERN Management GmbH and the Institute of Clinical Anatomy and Cell Analysis | Tübingen. These services are intended to help accelerate the translation of research findings into practice—for example, by identifying new areas of application and analysing requirements for data transfer and data management for secondary data use. The insights gained will support the further development of suitable frameworks and tailored services for collaboration between the medical technology industry and clinical care.
The shared goal: To open up new possibilities for precise, tissue-sparing and patient-centred treatment.
The project is being implemented as part of the industry-in-clinic platform AIM (Access for Innovation in Medical technology). Further information about AIM can be found HERE.
The collaborative project LtAPD-AI is funded by the German Federal Ministry of Research, Technology and Space (BMFTR) under the funding initiative “Establishing Industry-in-Clinic Platforms for the Development of Innovative Medical Devices”. The project began on 1 August 2026 and will run for three years.
BioRegio STERN Management GmbH